Aristotle University Of Thessaloniki (AUTH)
Μεταβολές των πολυδύναμων προγονικών κυττάρων του περιφερικού αίματος και των βιολογικών δεικτών νεογνών με περιγεννητική ασφυξία σε σχέση με τη νευροαναπτυξιακή έκβαση
Abstract
dc:descriptionPerinatal asphyxia and related neonatal encephalopathy are among the most common causes of neonatal death and long-term neurological deficits both in preterm and fullterm neonates. Modern therapeutic strategies in newborns with brain injury involve only supportive care (with the exception of therapeutic hypothermia in fullterm neonates who are admitted in Neonatal Intensive Care Unit within the first 6 hours if life), and therefore neonatal encephalopathy remains a basic target for regenerative medicine. On the other hand, progenitor cells do exist endogenously as well, especially referring to newborns. Therefore, a critical question is raised: what is the role of endogenous progenitor cells in neonates after brain injury? Do they participate in the endogenous regeneration process? To answer these critical questions, a prospective cohort study in preterm and fullterm neonates was designed, which took place in the 1st Neonatal Department of Aristotle University of Thessaloniki. 83 newborns were included in the present study (47 preterms and 36 fullterms) from December 2010 to November 2013. Neonates were observed from the first day of their life until they completed their second year of life (corrected age). Among preterms, 16 developed brain damage (II/III degree IVH, cystic PVL or infract), while 31 showed no apparent brain injury and served as preterm controls. Among fullterms, 13 developed moderate or severe encephalopathy, 11 developed mild encephalopathy, whereas 12 healthy neonates without any perinatal event comprised the group of fullterm controls. Peripheral blood was collected on days 1, 3, 9, 18 and 45 of life, as well as in the 8th and 24th month of life (corrected age). From these samples, Circulating Progenitor Cells (CPCs) were determined using Flow Cytometry, whereas brain injury markers (S100b and Neuronal Specific Enolase (NSE)) and chemoattractants/neurotrophic factors (erythropoietin (EPO) and Insulin-like growth factor-1 (IGF-1)) were measured using Immunochemiluminometric Assay (ICMA). Additionally, on the same days chemoattractant Stromal cell-Derived Factor-1 (SDF-1) was determined using ELISA. Regarding CPCs, cell populations of interest included Haematopoietic Stem Cells (HSCs, CD34+/CD184+/CD45+), Very Small Embryonic-like Stem Cells (VSELs, CD34+/CD184+/CD45-), early Endothelial Progenitor Cells (early EPCs, CD34+/CD45dim/- /CD184+/CD133+) and late Endothelial Progenitor Cells (late EPCs, CD34+/CD45dim/- /CD184+/CD133+). Perinatal characteristics and complications during the neonatal period were recorded, especially regarding neurological outcome. Preterms were assessed frequently using cranial ultrasound and all suspected brain injuries in preterms and fullterms were further elucidated using Magnetic Resonance Imaging (MRI) as appropriate. Quantification of lesions from MRI images was also performed. Moreover, all available children when they completed their second year of life (corrected age) underwent neurodevelopmental examination using Bayley III test.CPCs were mobilized in preterm and fullterm infants following brain injury in a chemotactic way, as part of an endogenous defence and regeneration mechanism against the hypoxic event and the related tissue damage. However, when the injury was severe, this mechanism was found to be insufficient in the first month of life, observation that is consistent with the occurrence of more severe neurodevelopmental deficits in these children. It is possible that exogenous administration of progenitor cells in the future, especially in cases of severe encephalopathy, might reinforce this endogenous insufficiency, reduce the extent of brain injury and improve the clinical outcome. Before exogenous administration of progenitor cells will be applied in clinical practice, critical issues must be elucidated, including the ultimate cell subtype, dose, route of administration, the appropriate time of administration, as well as the use of neurotrophic factors. The present study offers important data in pathophysiology regarding the role of biomarkers and endogenous CPCs in consecutive time-points. Personalized regeneration medicine could be the therapeutic strategy of choice in neonatal brain injury in the near future.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2015
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Efstathiou, Nikolaos
- Ευσταθίου, Νικόλαος
Subjects
dc:subject × 18Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/36587